The failure of the proteostasis network to maintain aggregation-prone proteins in their soluble-state is a major pathogenic mechanism underlying HD and other protein-folding diseases, for which the development of therapeutics to boost proteostasis capacity by targeting HSF1, has been proposed37–39. Here, HSF1 is linked to proteostasis deficiencies.